The IL-6/sIL-6R complex as a novel target for therapeutic approaches

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 5, 2007, Pages 613-624

  Rose John, Stefan ^a   Waetzig, Georg H ^b   Cheller, Jürgen ^a   Grötzinger, Joachim ^a   Seegert, Dirk ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b CONARIS Research Institute AG ^*  (Germany)

Author keywords

Colon cancer; Cytokine; IL 6; Inflammation; Receptor; Rheumatoid arthritis; Soluble; Trans signalling

Indexed keywords

ATLIZUMAB; ETANERCEPT; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 130 FC RECEPTOR; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL ACTIVITY; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLON CANCER; COMPLEX FORMATION; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; INFECTION; MEMBRANE BINDING; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RNA SPLICING; RNA TRANSLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; ULCERATIVE COLITIS; UPREGULATION;

ALTERNATIVE SPLICING; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; ASTHMA; AUTOIMMUNE DISEASES; CELL LINE; CLINICAL TRIALS; COLITIS; COLONIC NEOPLASMS; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES; MALE; MICE; NEOPLASMS; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 34248341267     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.5.613     Document Type: Review

References (119)

1. BAZAN JF: Haemopoietic receptors and helical cytokines. Immunol. Today (1990) 11(10)50-354.
2. HIRANO T, KISHIMOTO T: Molecular biology and immunology of interleukin-6. Res. Immunol. (1992) 143(7):723-724.
3. TAGA T, KISHIMOTO T: Gp130 and the interleukin-6 family of cytokines. Ann. Rev. Immunol. (1997) 15:797-819.
4. PFLANZ S, HIBBERT L, MATTSON J et al.: WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. (2004) 172(4):2225-2231.
5. MURAKAMI M, KAMIMURA D, HIRANO T: New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors (2004) 22(2):75-77.
6. DILLON SR, SPRECHER C, HAMMOND A et al.: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. (2004) 5(7):752-760.
7. BOULANGER MJ, CHOW DC, BREVNOVA EE, GARCIA KC: Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex. Science (2003) 300(5628):2101-2104.
8. GROTZINGER J, KERNEBECK T, KALLEN KJ, ROSE-JOHN S: IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol. Chem. (1999) 380(7-8):803-813.
9. GROTZINGER J: Molecular mechanisms of cytokine receptor activation. Biochem. Biophys. Acta (2002) 1592(3):215-223.
10. TAGA T: IL6 signalling through IL6 receptor and receptor-associated signal transducer, gp130. Res. Immunol. (1992) 143(7):737-739.
11. MULLBERG J, SCHOOLTINK H, STOYAN T, HEINRICH PC, ROSE-JOHN S: Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem. Biophys. Res. Commun. (1992) 189(2):794-800.
12. MULLBERG J, SCHOOLTINK H, STOYAN T et al.: The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. (1993) 23(2):473-480.
13. LUST JA, DONOVAN KA, KLINE MP et al.: Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 4(2):96-100.
14. HORIUCHI S, KOYANAGI Y, ZHOU Y et al.: Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. (1994) 24(8):1945-1948.
15. MACKIEWICZ A, SCHOOLTINK H, HEINRICH PC, ROSE-JOHN S: Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. (1992) 149(6):2021-2027.
16. ROSE-JOHN S, HEINRICH PC: Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. (1994) 300(Pt. 2):281-290.
17. PETERS M, MULLER AM, ROSE-JOHN S: Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 92(10):3495-3504.
18. PETERS M, SCHIRMACHER P, GOLDSCHMITT J et al.: Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J. Exp. Med. (1997) 185(4):755-766.
19. HACKER C, KIRSCH RD, JU XS et al.: Transcriptional profiling identifies Id2 function in dendritic cell development. Nat. Immunol. (2003) 4(4):380-386.
20. + cells. Stem Cells (2006) 24(5):1302-1314.
21. ATREYA R, MUDTER J, FINOTTO S et al.: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. (2000) 6(5):583-588.
22. BECKER C, FANTINI MC, SCHRAMM C et al.: TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 21(4):491-501.
23. BECKER C, FANTINI MC, WIRTZ S et al.: IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 4(2):217-220.
24. ROSE-JOHN S: GP130 stimulation and the maintenance of stem cells. Trends Biotechnol. (2002) 20(10):417-419.
25. HUMPHREY RK, BEATTIE GM, LOPEZ AD et al.: Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells (2004) 22(4):522-530.
26. MARZ P, CHENG JG, GADIENT RA et al.: Sympathetic neurons can produce and respond to interleukin 6. Proc. Natl. Acad. Sci. USA (1998) 95(6):3251-3256.
27. MARZ P, OTTEN U, ROSE-JOHN S: Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur. J. Neurosci. (1999) 11(9):2995-3004.
28. MARZ P, HEESE K, DIMITRIADES-SCHMUTZ B, ROSE-JOHN S, OTTEN U: Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia (1999) 26(3):191-200.
29. KLOUCHE M, BHAKDI S, HEMMES M, ROSE-JOHN S: Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J. Immunol. (1999) 163(8):4583-4589.
30. HURST SM, WILKINSON TS, MCLOUGHLIN RM et al.: Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 14(6):705-714.
31. MCLOUGHLIN RM, WITOWSKI J, ROBSON RL et al.: Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J. Clin. Invest. (2003) 112(4):598-607.
32. ROMANO M, SIRONI M, TONIATTI C et al.: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 6(3):315-325.
33. WANG XP, SCHUNCK M, KALLEN KJ et al.: The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J. Invest. Dermatol. (2004) 123(1):124-131.
34. GAULDIE J, RICHARDS C, HARNISH D, LANSDORP P, BAUMANN H: Interferon β 2/B-cell stimulatory factor Type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. USA (1987) 84(20):7251-7255.
35. AKIRA S, TAGA T, KISHIMOTO T: Interleukin-6 in biology and medicine. Adv. Immunol (1993) 54:1-78.
36. PETERS M, MEYER ZUM BUSCHENFELDE KH, ROSE-JOHN S: The function of the soluble IL-6 receptor in vivo. Immunol Lett. (1996) 54(2-3):177-184.
37. NISHIMURA R, MORIYAMA K, YASUKAWA K, MUNDY GR, YONEDAT: Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J. Bone Miner. Res. (1998) 13(5):777-785.
38. MITSUYAMA K, SASAKI E, TOYONAGA A et al.: Colonic mucosal interleukin-6 in inflammatory bowel disease. Digestion (1991) 50(2):104-111.
39. GROSS V, ANDUS T, CAESAR I, ROTH M, SCHOLMERICH J: Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology (1992) 102(2):514-519.
40. REINECKER HC, STEFFEN M, WITTHOEFT T et al.: Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol (1993) 94(1):174-181.
41. MITSUYAMA K, TOYONAGA A, SASAKI E et al.: Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut (1995) 36(1):45-49.
42. HOSOKAWA T, KUSUGAMI K, INA K et al.: Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. (1999) 14(10):987-996.
43. KEUL R, HEINRICH PC, MULLER-NEWEN G, MULLER K, WOO P: A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine (1998) 10(9):729-734.
44. KOTAKE S, SATO K, KIM KJ et al.: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. (1996) 11(1):88-95.
45. ROBAK T, GLADALSKA A, STEPIEN H, ROBAK E: Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. (1998) 7(5):347-353.
46. YOKOYAMA A, KOHNO N, FUJINO S et al.: Circulating interleukin-6 levels in patients with bronchial asthma. Am. J. Respir. Crit. Care Med. (1995) 151 (5):1354-1358.
47. YOKOYAMA A, KOHNO N, HIRASAWA Y et al.: Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin. Exp. Immunol. (1995) 100(2):325-329.
48. JILKA RL, HANGOC G, GIRASOLE G et al.: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 257(5066):88-91.
49. MANOLAGAS SC, JILKA RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med (1995) 332(5):305-311.
50. STRASSMANN G, FONG M, KENNEY JS, JACOB CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. (1992) 89(5):1681-1684.
51. BARAK V, SCHWARTZ A, KALICKMAN I et al.: Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am. J. Med. (1998) 104(1):40-47.
52. PALLUA N, LOW JF, VON HEIMBURG D: Pathogenic role of interleukin-6 in the development of sepsis. Part II: significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-α antibodies in a standardized murine contact burn model. Crit. Care Med. (2003) 31(5):1495-1501.
53. HORII Y, MURAGUCHI A, IWANO M et al.: Involvement of IL-6 in mesangial proliferative glomerulonephritis. J. Immunol. (1989) 143(12):3949-3955.
54. PADBERG F, FENEBERG W, SCHMIDT S et al.: CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J. Neuroimmunol. (1999) 99(2):218-223.
55. MARZ P, HEESE K, HOCK C et al.: Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. (1997) 239(1):29-32.
56. HAMPEL H, SUNDERLAND T, KOTTER HU et al.: Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. Brain Res. (1998) 780(2):356-359.
57. JERNBERG-WIKLUND H, PETTERSSON M, CARLSSON M, NILSSON K: Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia (1992) 6(4):310-318.
58. BARUT BA, ZON LI, COCHRAN MK et al.: Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk. Res. (1992) 16(10):951-959.
59. YOSHIZAKI K, MATSUDA T, NISHIMOTO N et al.: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood (1989) 74(4):1360-1367.
60. TESCH H, JUCKER M, KLEIN S et al.: Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors. Leuk. Lymphoma (1992) 7(4):297-303.
61. SHIROTA K, LEDUY L, YUAN SY, JOTHY S: Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. (1990) 58(4):303-308.
62. HONDA M, YAMAMOTO S, CHENG M et al.: Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. (1992) 148(7):2175-2180.
63. HORIUCHI S, AMPOFO W, KOYANAGI Y et al.: High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy. Immunology (1998) 95(3):360-369.
64. POLI G, BRESSLER P, KINTER A et al.: Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post-transcriptional mechanisms. J. Exp. Med (1990) 172(1):151-158.
65. NISHIMOTO N, KISHIMOTO T: Inhibition of IL-6 for the treatment of inflammatory diseases. Curr. Opin. Pharmacol. (2004) 4(4):386-391.
66. SMOLEN JS, MAINI RN: Interleukin-6: a new therapeutic target. Arthritis Res. Ther. (2006) 8(Suppl. 2):S5.
67. BASELGA J, MENDELSOHN J: Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol. Ther. (1994) 64(1):127-154.
68. TRIKHA M, CORRINGHAM R, KLEIN B, ROSSI JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. (2003) 9(13):4653-4665.
69. WENDLING D, RACADOT E, WIJDENES J: Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. (1993) 20(2):259-262.
70. SUZUKI Y, YANG Q, CONLEY FK, ABRAMS JS, REMINGTON JS: Antibody against interleukin-6 reduces inflammation and numbers of cysts in brains of mice with toxoplasmic encephalitis. Infect. Immun. (1994) 62(7):2773-2778.
71. GIJBELS K, BROCKE S, ABRAMS JS, STEINMAN L: Administration of neutralizing antibodies to interleukin-6 (IL-6) reduces experimental autoimmune encephalomyelitis and is associated with elevated levels of IL-6 bioactivity in central nervous system and circulation. Mol. Med. (1995) 1(7):795-805.
72. NISHIMOTO N: Anti-interleukin-6 receptor antibody therapy - from bedside to bench. Nihon Rinsho Meneki Gakkai Kaishi (2006) 29(5):289-294.
73. MIHARA M, NISHIMOTO N, OHSUGI Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin. Biol. Ther. (2005) 5(5):683-690.
74. YOKOTA S, MIYAMAE T, IMAGAWA T et al.: Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. (2005) 52(3):818-825.
75. ECONOMIDES AN, CARPENTER LR, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9(1):47-52.
76. METZ S, WIESINGER M, VOGT M et al.: Characterization of the interleukin-6 inhibitor IL-6-RFP: Fused receptor domains act as high-affinity cytokine-binding proteins. J. Biol. Chem. (2006) Epub ahead of print.
77. JOSTOCK T, MULLBERG J, OZBEK S et al.: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. (2001) 268(1):160-167.
78. ELSON GC, LELIEVRE E, GUILLET C et al.: CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat. Neurosci. (2000) 3(9):867-872.
79. HEINRICH PC, BEHRMANN I, MULLER-NE WEN G, SCHAPER F, GRAEVE L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. (1998) 334(Pt. 2):297-314.
80. TAGA T, KISHIMOTO T: Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr. Opin. Immunol. (1995) 7(1):17-23.
81. SCHROERS A, HECHT O, KALLEN KJ et al.: Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci. (2005) 14(3):783-790.
82. PFLANZ S, KURTH I, GROTZINGER J, HEINRICH PC, MULLER-NEWEN G: Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J. Immunol. (2000) 165(12):7042-7049.
83. MULLBERG J, DITTRICH E, GRAEVE L et al.: Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett. (1993) 332(1-2):174-178.
84. MULLBERG J, OBERTHUR W, LOTTSPEICH F et al.: The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J. Immunol (1994) 152(10):4958-4968.
85. TAGA T, HIBI M, HIRATA Y et al.: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 58(3):573-581.
86. NARAZAKI M, YASUKAWA K, SAITO T et al.: Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood (1993) 82(4):1120-1126.
87. MULLER-NEWEN G, KUSTER A, HEMMANN U et al.: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J. Immunol. (1998) 161(11):6347-6355.
88. KLOUCHE M, ROSE-JOHN S, SCHMIEDT W, BHAKDI S: Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation (2000) 101(15):1799-1805.
89. MODUR V, LI Y, ZIMMERMAN GA, PRESCOTT SM, MCINTYRE TM: Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor α. J. Clin. Invest. (1997) 100(11):2752-2756.
90. BARTON BE, JACKSON JV: Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. (1993) 61(4):1496-1499.
91. XING Z, GAULDIE J, COX G et al.: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin.Invest. (1998) 101(2):311-320.
92. JOSTOCK T, BLINN G, RENNE C et al.: Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. J. Immunol. Methods (1999) 223(2):171-183.
93. SILACCI P, DAYER JM, DESGEORGES A et al.: Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J. Biol. Chem. (1998) 273(22):13625-13629.
94. YASUKAWA K, FUTATSUGI K, SAITO T et al.: Association of recombinant soluble IL-6-signal transducer, gp 130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol. Lett. (1992) 31(2):123-130.
95. MONTERO-JULIAN FA, BRAILLY H, SAUTES C et al.: Characterization of soluble gp130 released by melanoma cell lines: a polyvalent antagonist of cytokines from the interleukin 6 family. Clin. Cancer Res. (1997) 3(8):1443-1451.
96. SCHELLER J, SCHUSTER B, HOLSCHER C, YOSHIMOTO T, ROSE-JOHN S: No inhibition of IL-27 signaling by soluble gp130. Biochem. Biophys. Res. Commun. (2005) 326(4):724-728.
97. DIAMANT M, RIENECK K, MECHTI N et al.: Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. (1997) 412(2):379-384.
98. SCHELLER J, KOVALEVA M, RABE B et al.: Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition. J. Immunol. Methods (2004) 291(1-2):93-100.
99. + T cells. Immunity (1994) 1(7):553-562.
100. BOUGHTON-SMITH NK, WALLACE JL, MORRIS GP, WHITTLE BJ: The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br. J. Pharmacol. (1988) 94(1):65-72.
101. MITSUYAMA K, MATSUMOTO S, ROSE-JOHNS et al.: STAT3 activation via interleukin-6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut (2006) Epub ahead of print.
102. RAKEMANN T, NIEHOF M, KUBICKA S et al.: The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J. Biol. Chem. (1999) 274(3):1257.
103. CHOY EH, ISENBERG DA, GARROOD T et al.: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. (2002) 46(12):3143-3150.
104. GARDAM MA, KEYSTONE EC, MENZIES R et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. (2003) 3(3):148-155.
105. DEBANDT M, VITTECOQ O, DESCAMPS V, LE LOET X, MEYER O: Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol. (2003) 22(1):56-61.
106. SCHELLER J, ROSE-JOHN S: Interleukin-6 and its receptor: from bench to bedside. Med. Microbiol. Immunol. (Berl) (2006) 195(4):173-183.
107. NOWELL MA, RICHARDS PJ, HORIUCHI S et al.: Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. (2003) 171(6):3202-3209.
108. KALLEN KJ: The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta (2002) 1592(3):323-343.
109. OHSHIMA S, SAEKI Y, MIMA T et al.: Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc. Natl. Acad. Sci. USA (1998) 95(14):8222-8226.
110. ALONZI T, FATTORI E, LAZZARO D et al.: Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. (1998) 187(4):461-468.
111. DOGANCI A, SAUER K, KARWOT R, FINOTTO S: Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin. Rev. Allergy Immunol. (2005) 28(3):257-270.
112. reg development and function during allergic airway inflammation in vivo. J. Clin. Invest. (2005) 115(2):313-325.
113. + T cell-mediated suppression by dendritic cells. Science (2003) 299(5609):1033-1036.
114. NISHIMOTO N, YOSHIZAKI K, MIYASAKA N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50(6):1761-1769.
115. DINARELLO CA: Anti-cytokine therapeutics and infections. Vaccine (2003) 21(Suppl. 2):S24-S34.
116. EHLERS S: Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J. Rheumatol. Suppl. (2005) 74:35-39.
117. SYMMONS DP, SILMAN AJ: The world of biologics. Lupus (2006) 15(3):122-126.
118. ITO H: Novel therapy for Crohn's disease targeting IL-6 signalling. Expert Opin. Ther. Targets (2004) 8(4):287-294.
119. DING C, JONES G: Technology evaluation: MRA, Chugai. Curr. Opin. Mol. Ther. (2003) 5(1):64-69.